Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
- PMID: 38225288
- PMCID: PMC10789731
- DOI: 10.1038/s41467-024-44786-2
Generation and optimization of off-the-shelf immunotherapeutics targeting TCR-Vβ2+ T cell malignancy
Abstract
Current treatments for T cell malignancies encounter issues of disease relapse and off-target toxicity. Using T cell receptor (TCR)Vβ2 as a model, here we demonstrate the rapid generation of an off-the-shelf allogeneic chimeric antigen receptor (CAR)-T platform targeting the clone-specific TCR Vβ chain for malignant T cell killing while limiting normal cell destruction. Healthy donor T cells undergo CRISPR-induced TRAC, B2M and CIITA knockout to eliminate T cell-dependent graft-versus-host and host-versus-graft reactivity. Second generation 4-1BB/CD3zeta CAR containing high affinity humanized anti-Vβ scFv is expressed efficiently on donor T cells via both lentivirus and adeno-associated virus transduction with limited detectable pre-existing immunoreactivity. Our optimized CAR-T cells demonstrate specific and persistent killing of Vβ2+ Jurkat cells and Vβ2+ patient derived malignant T cells, in vitro and in vivo, without affecting normal T cells. In parallel, we generate humanized anti-Vβ2 antibody with enhanced antibody-dependent cellular cytotoxicity (ADCC) by Fc-engineering for NK cell ADCC therapy.
© 2024. The Author(s).
Conflict of interest statement
J.R., X.L., J.M.L. and M.G are inventors on patent applications filed by Yale University. Application # 63/484,916. The remaining authors declare no competing interests.
Figures
![Fig. 1](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10789731/bin/41467_2024_44786_Fig1_HTML.gif)
![Fig. 2](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10789731/bin/41467_2024_44786_Fig2_HTML.gif)
![Fig. 3](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10789731/bin/41467_2024_44786_Fig3_HTML.gif)
![Fig. 4](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10789731/bin/41467_2024_44786_Fig4_HTML.gif)
![Fig. 5](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10789731/bin/41467_2024_44786_Fig5_HTML.gif)
![Fig. 6](https://cdn.statically.io/img/www.ncbi.nlm.nih.gov/pmc/articles/instance/10789731/bin/41467_2024_44786_Fig6_HTML.gif)
Similar articles
-
Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.Front Immunol. 2020 Aug 7;11:1965. doi: 10.3389/fimmu.2020.01965. eCollection 2020. Front Immunol. 2020. PMID: 32903482 Free PMC article. Review.
-
Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR.Blood. 2020 Sep 17;136(12):1407-1418. doi: 10.1182/blood.2020005185. Blood. 2020. PMID: 32483603 Free PMC article.
-
Universal allogeneic CAR T cells engineered with Sleeping Beauty transposons and CRISPR-CAS9 for cancer immunotherapy.Mol Ther. 2022 Oct 5;30(10):3155-3175. doi: 10.1016/j.ymthe.2022.06.006. Epub 2022 Jun 16. Mol Ther. 2022. PMID: 35711141 Free PMC article.
-
Precision Engineering of an Anti-HLA-A2 Chimeric Antigen Receptor in Regulatory T Cells for Transplant Immune Tolerance.Front Immunol. 2021 Sep 20;12:686439. doi: 10.3389/fimmu.2021.686439. eCollection 2021. Front Immunol. 2021. PMID: 34616392 Free PMC article.
-
Off-the-Shelf Chimeric Antigen Receptor T Cells: How Do We Get There?Cancer J. 2021 Mar-Apr 01;27(2):176-181. doi: 10.1097/PPO.0000000000000511. Cancer J. 2021. PMID: 33750078 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials
Miscellaneous